Search PubMed⌕ Search

Biomedical subjects

M Ishida

Publications and source records attributed to M Ishida.

At least 541 records · Page 30Linked to original sources
PubMed1981

Clinical study on increased serum thyroxine-binding globulin in cancerous state.

Serum thyroxine-binding globulin (TBG) in 169 patients with various cancers was determined by radioimmunoassay (RIA). Eleven patients showed a high serum TBG level (greater than 35 micrograms/ml). Two of them had been treated with estrogen for prostate cancer. One patient had high serum TBG with serum hepatitis. Another 8 cases had normal liver function and also normal levels serum estrogen. Thus, about 4.7% (8/169) of the cancer patients had high serum TBG and mild hyperthyroxinemia caused by unknown mechanisms. The high TBG level in these patients continued until just before death, or in some cases decreased to normal after removal of cancer tumors by operation. Cancer is occasionally associated with an increase in serum TBG. Although the mechanism is not clear, the increased TBG in the cancerous state in interesting and has significance as a tumor marker.

Adult↗
PubMed1981

Hepatic resection upon patients with jaundice.

Fourteen jaundiced patients with carcinoma at the bifurcation of the hepatic ducts, primary carcinoma of the liver and congenital cystic dilation of the intrahepatic bile ducts underwent hepatic resection without an operative mortality after the jaundice was relieved preoperatively. All patients did well, with jaundice and fever being absent postoperatively, although nine patients died of a recurrence of carcinoma in the follow-up period. It is now clear that the jaundiced patient become candidates for hepatic resection.

Adult↗
PubMed1980

Inhibitory action of ibotenic acid on the crayfish neuromuscular junction.

The effect of ibotenic acid on the crayfish neuromuscular junction was investigated. Ibotenate reduced dose-dependently the amplitude of the excitatory junctional potentials (EJPs) elicited by repetitive stimulation of the excitatory axons. Ibotenate did not affect facilitation of successive EJPs. The decrease in the EJP amplitude caused by ibotenate was almost completely blocked by picrotoxin. A quantum analysis of extracellularly recorded EJPs demonstrated that the mean quantum content was reduced by ibotenate without remarkable change in unit size. Ibotenate increased the conductance change induced by ibotenate was observed even if the glutamate receptor was completely desensitized by the prolonged application of glutamate. From an analysis of the dose-response curve of GABA with or without ibotenate, it is suggested that ibotenate acts on the GABA receptor in the crayfish neuromuscular junction.

Animals↗
PubMed1980

A specific competitive protein binding assay for serum 24,25-dihydroxyvitamin D in normal children and patients with nephrotic syndrome.

A specific competitive protein binding assay for 24,25-dihydroxyvitamin D by Sephadex LH-20 column chromatography, followed by high pressure liquid chromatography with normal rat kidney cytosol as the binding protein, was developed. The mean concentrations of serum 24,25-dihydroxyvitamin D of the cord, in newborn infants and in infants under 12 months of age were 0.90 +/- 0.40 (S.D.) ng/ml, 0.52 +/- 0.21 (S.D.) ng/ml and 1.20 +/- 0.38 (S.D.) ng/ml, respectively. These concentrations were significantly lower than those in children aged 1-15 years (1.96 +/- 0.83 (S.D.) ng/ml). The serum levels in the acute stage of the nephrotic syndrome were significantly reduced, and they increased in remission. These results show that patients wioth nephrotic syndrome have low levels of serum 24,25-dihydroxyvitamin D. This is probably due to its loss in the urine.

24,25-Dihydroxyvitamin D 3↗
PubMed1980

Differential diagnosis of hypoparathyroid disorders during childhood.

Changes in the plasma and urinary adenosine 3', 5' monophosphate (cyclic AMP) levels on infusion of parathyroid hormone were studied in 10 normal children, 5 children with idiopathic hypoparathyroidism, and 3 children with pseudohypoparathyroidism. In normal children the plasma concentration of cyclic AMP ranges from 18.0 to 68.0 pmoles/ml under basal conditions, and increases to a peak of about 10-fold the basal level 5 min after infusion of parathyroid hormone. Infusion of parathyroid hormone caused no increase in plasma cyclic AMP in patients with pseudohypoparathyroidism but about 18-fold increase in those with idiopathic hypoparathyroidism. The measurement of plasma cyclic AMP before and 5 min after infusion of parathyroid hormone is concluded to be a single and effective method for differential diagnosis of hypoparathyroid disorders.

Child↗
PubMed1980

Plasma 1,25-dihydroxyvitamin D concentrations in cords, newborns, infants, and children.

Plasma 1,25-dihydroxyvitamin D [1,25-(OH)2-D] was measured in cord serum, newborns, infants, and children. The mean for the values obtained from the six cords was significantly higher than the mean for the older children (6-15 years). The mean for the six newborns (0-1 week) was significantly higher than that for the older children. The mean for the nine infants (1 week-6 months) and the 14 younger children (6 months-6 years) was significantly higher than that for older children. The present study suggests that the perinatal period is associated with a marked increase in 1,25-(OH)2-D.

Adolescent↗
PubMed1980

Clinical study of niceritrol on serum lipids in the treatment of hyperlipidemia.

The effects of niceritrol, a nicotinic acid derivative, on the levels of HDL-cholesterol (HDL-Ch) and a mixture of VLDL- and LDL-Ch (VLDL- + LDL-Ch) were studied in hyperlipidemic patients. Serum total cholesterol (sTC) and serum triglyceride (sTG) were significantly reduced during niceritrol administration. Lipoprotein electrophoresis showed that niceritrol increased the alpha:beta ratio. HDL-Ch showed a significant increase of 12.5% by the 16th week of therapy. This increase was more marked in patients with lower pre-treatment HDL-Ch levels and significant in patients whose pre-treatment sTG levels were in excess of 200 mg/dl. Females displayed higher pre-treatment HDL-Ch levels (38.5 mg/dl) than males (30.6 mg/dl). However, niceritrol increased HDL-Ch significantly in both groups. At 16 weeks, the VLDL- + LDL-Ch level showed a significant decrease of 9.2%; the HDL-Ch:VLDL + LDL-Ch and HDL-CH:sTC ratios were significantly increased throughout niceritrol administration. Niceritrol is thought to be effective in preventing the development and progression of atherosclerosis because it raises the level of anti-atherogenic HDL-Ch and lowers the level of atherogenic VLDL- + LDL-Ch.

Cholesterol↗
PubMed1980

Differential effects of diltiazem on glutamate potentials and excitatory junctional potentials at the crayfish neuromuscular junction.

1. The effects of diltiazem on glutamate potentials and excitatory junctional potentials (e.j.p.s) were investigated in the crayfish neuromuscular junction. 2. When diltiazem (0.3 mM) was added to the perfusion fluid, the ionophoretic glutamate potential was reduced to about half, whereas the peak amplitude of successive e.j.p.s elicited by a train of pulses of 100/sec increased by about 2 times. 3. It was suggested that diltiazem was a non-competitive inhibitor of L-glutamate. The reduction of the response to applied glutamate was not due to the acceleration of desensitization of the glutamate receptor. The rate of recovery from desensitization was delayzed by diltiazem. 4. The increase in amplitude of e.j.p.s caused by diltiazem was due to the increase in membrane resistance. The quantum content and size of extracellular e.j.p.s were not affected by diltiazem. 5. It was substantiated using the micro-electrode technique that the glutamate sensitive area coincided with the neuromuscular junctional area. 6. The pharmacological difference between glutamate potentials and e.j.p.s revealed in the present study is difficult to explain on the glutamate transmitter hypothesis. One explanation worthy to be considered is that there are two pharmacologically different kinds of receptors sensitive to L-glutamate.

Animals↗
PubMed1980

Treatment of hypophosphataemic vitamin D-resistant rickets with massive doses of 1 alpha-hydroxy-vitamin D3 during childhood.

Plasma levels of 1,25 dihydroxy-vitamin D (1,25-(OH)2-D) were low in 3 children with hypophosphataemic vitamin D-resistant rickets (HVDRR) during childhood, but increased after very large doses (0.5 to 2 micrograms/kg per day) of 1 alpha-hydroxy-vitamin D (1 alpha-OH-D3). This treatment has two advantages. Firstly, hypercalcaemia is easily controlled by reducing the dose of 1 alpha-OH-D3 because of its short half-life. Secondly, the administration of 1 alpha-OH-D3 to patients with HVDRR can enhance the tubular reabsorption of phosphate, and this seems desirable in treating HVDRR.

Adolescent↗
PubMed1980

Vitamin D metabolism in hypophosphatemic vitamin D-resistant rickets.

Plasma levels of 1,25-(OH)2-D were low in children with hypophosphatemic vitamin D-resistant rickets (HVDRR), but increased after very large doses of 1 alpha-OH-D3. These results suggest that the metabolism of 1,25-(OH)2-D is accelerated in HVDRR. In addition, the lower level of plasma 1,25-(OH)2-D in untreated HVDRR was correlated with the lower level of serum phosphate and renal threshold phosphate concentration (TmP/GFR). The administration of 1 alpha-OH-D3 to the patients with HVDRR could enhance the renal threshold phosphate concentration.

Alkaline Phosphatase↗